Kazatomprom said in a statement that its revenue from selling U3O8 in 2022 is now expected to be about $1.8bn (€1.7bn) from a previously forecasted $1.4bn.
The statement said the company’s sales volumes in the first quarter of 2022 were about twice higher than volumes for the same period in 2021. The fluctuation can be explained by the timing of customer-scheduled deliveries, which usually vary substantially each quarter.
Want to keep reading?
Register free and get full access to NucNet for 14 days. No card required.
- Daily news briefing on the global nuclear industry
- Weekly, monthly and topical newsletters
- 24/7 coverage during nuclear incidents and safety events
- Full searchable archive, 30,000+ articles since 1991
- SMR and AMR project database
- Analysis, Focus pieces and infographics
- NucNet Style Guide for nuclear reporters and communicators
After the trial, keep a free account for a newsletter and a complimentary Plus article every two weeks. Or see our subscription plans for individuals and organisations.
See subscription options